Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote & News

Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fix...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 682 0917

Website: amylyx.com

Address:

43 Thorndike Street, Cambridge, United States

StockConsultant Feb. 3 at 2:24 AM

$AMLX Amylyx Pharmaceuticals stock watch, pullback to 14.54 triple+ support area with bullish indicators at https://stockconsultant.com/?AMLX

0 · Reply

codename41 Feb. 2 at 9:25 PM

$AMLX 🍸

1 · Reply

codename41 Jan. 30 at 7:57 PM

$AMLX loaded

0 · Reply

ajmore Jan. 30 at 4:15 PM

$AMLX Nasdaq short data is out. 13.4 mln shares! thats like 18% of free-float. very similar to $GME .

1 · Reply

ajmore Jan. 29 at 5:22 PM

$AMLX the trial design: two groups, 45 and 30. the 30 alternate days with avexitide and days with placebo. the 45 take the real drug. why this makes a difference: if the 45 group consistently showing improvement on all days (average, recall its regression ols) and the 30 showing alternate consistent pattern then: chatgpt: "The honest bottom line You’re right: Seeing one group better all the time and the other better only on some days is a very strong indicator of efficacy, not just random confidence. It’s not legally “proof” until unblinded and analyzed — but scientifically, it’s already persuasive." hopefully our hunch is right!

1 · Reply

ajmore Jan. 29 at 7:02 AM

$AMLX Is it easier to conclude the drug works toward the end of the trial? chatgpt: As the trial progresses: More participants complete follow-up More outcome events are observed Variance shrinks Confidence intervals narrow So if the drug truly works, the signal-to-noise ratio improves over time, making statistical significance more likely by the end.

1 · Reply

ajmore Jan. 29 at 6:14 AM

$AMLX Selling with the pharma etf. All intact and the fact that insiders are holding and ceos even increased their shares is very reassuring. Technicals! short interest must be around 14mln (and not 3 mln as on couple of market systems). 14mln!. To put in perspective, the short interest and number of days to cover is similar to $GME , yes game stop. Maybe higher in terms of free float. On Monday we see Nasdaq filing. many catalysts coming our way.

0 · Reply

SocioCobb Jan. 27 at 3:40 PM

$AMLX Remain a bull here 👍!

1 · Reply

SilentBull69 Jan. 26 at 11:39 PM

$AMLX I feel like I’m on a yo-yo

1 · Reply

ajmore Jan. 24 at 12:30 PM

$AMLX bit more on ASOs, not boring I promise: https://ecancer.org/en/news/24590-next-generation-treatments-hitch-a-ride-into-cancer-cells L687 compound discovered by scientists from osaka uni, opens a permeable calcium channels in cancer cells and allows ASOs to get into the cell. Whys this so important to Amylyx! Amylyx platform can derive ASOs, which means amylyx can quickly target other diseases, potentially lung, pancreatic and prostate cancers. This makes the company a screaming acquisition target, even beyond the avexitide and amx0114 and wolfram! we could see a beauty competition and a bidding war. Its a win win for investors, delivering cures and making profit.

1 · Reply

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Jan 8, 2026, 7:00 AM EST - 26 days ago

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

Dec 5, 2025, 9:00 AM EST - 2 months ago

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Dec 3, 2025, 7:53 PM EST - 2 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 13, 2025, 2:40 PM EST - 2 months ago

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Nov 6, 2025, 2:06 PM EST - 3 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 3 months ago

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Oct 30, 2025, 9:00 AM EDT - 3 months ago

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 27, 2025, 12:20 PM EDT - 3 months ago

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 16, 2025, 4:40 PM EDT - 3 months ago

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

Sep 10, 2025, 12:06 AM EDT - 5 months ago

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Sep 9, 2025, 4:01 PM EDT - 5 months ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 8, 2025, 9:01 PM EDT - 5 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 6:14 PM EDT - 5 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 27, 2025, 7:28 AM EDT - 5 months ago

Amylyx to stop development of rare brain disorder drug after trial failure

Aug 27, 2025, 7:00 AM EDT - 5 months ago

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Aug 26, 2025, 9:00 AM EDT - 5 months ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 7, 2025, 10:35 PM EDT - 6 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 9:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 21, 2025, 4:26 PM EDT - 7 months ago

Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential

Jul 14, 2025, 2:15 PM EDT - 7 months ago

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

Jul 13, 2025, 5:00 PM EDT - 7 months ago

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Jul 8, 2025, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

Jun 24, 2025, 2:59 PM EDT - 8 months ago

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market

Jun 17, 2025, 10:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 15, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

Jun 8, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Jun 3, 2025, 7:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Jun 1, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

May 29, 2025, 10:05 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

May 27, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 21, 2025, 7:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 12, 2025, 7:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 11, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

May 10, 2025, 11:19 AM EDT - 9 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

May 8, 2025, 7:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 8:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

May 4, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out

May 1, 2025, 9:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 30, 2025, 7:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

StockConsultant Feb. 3 at 2:24 AM

$AMLX Amylyx Pharmaceuticals stock watch, pullback to 14.54 triple+ support area with bullish indicators at https://stockconsultant.com/?AMLX

0 · Reply

codename41 Feb. 2 at 9:25 PM

$AMLX 🍸

1 · Reply

codename41 Jan. 30 at 7:57 PM

$AMLX loaded

0 · Reply

ajmore Jan. 30 at 4:15 PM

$AMLX Nasdaq short data is out. 13.4 mln shares! thats like 18% of free-float. very similar to $GME .

1 · Reply

ajmore Jan. 29 at 5:22 PM

1 · Reply

ajmore Jan. 29 at 7:02 AM

1 · Reply

ajmore Jan. 29 at 6:14 AM

0 · Reply

SocioCobb Jan. 27 at 3:40 PM

$AMLX Remain a bull here 👍!

1 · Reply

SilentBull69 Jan. 26 at 11:39 PM

$AMLX I feel like I’m on a yo-yo

1 · Reply

ajmore Jan. 24 at 12:30 PM

1 · Reply

ajmore Jan. 24 at 8:37 AM

$AMLX cont... The fact that amylyx already got one ASO into phase 1 proves that amylyx, will be able to create other variants and tackle further orphan diseases.

0 · Reply

ajmore Jan. 24 at 8:32 AM

$AMLX what is AMX0114 its an ASO, a new approach to disease treatment. https://www.pharmasalmanac.com/articles/potential-applications-for-antisense-oligonucleotide-therapies-continue-to-expand "ASOs are different from traditional small molecule and even newer biologic drugs, because they address problems associated with protein expression (over- or underproduction or production of mutated proteins) rather than the proteins themselves.3 The ability to target specific pre-mRNA through careful design typically results in a low level of side effects with ASO therapies and allows the development of highly personalized treatments addressing patient-specific mutations. In addition, ASOs make it possible to target proteins involved in disease mechanisms that were previously thought to be undruggable." considered very safe, without any worrying side effects as it targets themature mRNA and not the dna, literally blocking the production of the harmful proteins.

0 · Reply

ajmore Jan. 23 at 8:51 PM

$AMLX make sure youre not sitting on any short before the close 😀

0 · Reply

ajmore Jan. 22 at 9:17 PM

$AMLX chart today shows shorting, expected after nice move. squeeze will continue especially when nasdaq publishes the true extent of short and those that relied on their erroneous data will have to close. rally in place and justified and 20 on the cards. if you read the news about the amx0318 you would have noticed in their wording...and other diseases.

0 · Reply

ajmore Jan. 21 at 11:00 AM

$AMLX In full filing: CEO's increased holdings by ~62k shares each.

2 · Reply

RunnerSignals Jan. 20 at 9:10 PM

Top Stock Market Warriors $SIDU $DAWN $LPTH $AMLX $APPS started the day in the red but fought back like true Market Warriors, ending up double-digit gains!

0 · Reply

TeeMan123 Jan. 20 at 8:39 PM

$AMLX stock is moving positively, as it should, given the below article.. bodes well for Wolfram, bodes incredibly fantastic for the ALS program if it shows efficacy when they share this data…. My guess is someone knows the ALS data https://www.fda.gov/news-events/press-announcements/fda-issues-guidance-modernizing-statistical-methods-clinical-trials

0 · Reply

dogfish90ipa Jan. 20 at 8:28 PM

$AMLX Me think some shorts forgot to cover

0 · Reply

LoveRetailFroth Jan. 20 at 8:13 PM

$AMLX By the way my 60k shares are LT today 🍺 Give me 43.90 🚀

0 · Reply

LoveRetailFroth Jan. 20 at 8:08 PM

$AMLX @ajmore Is $100 a possibility here ? and the horizon? Thanks

0 · Reply

topstockalerts Jan. 20 at 7:05 PM

$AMLX Making a move as buyers step in. Price is starting to break away from the range. Momentum is clearly shifting.

0 · Reply

ajmore Jan. 20 at 6:04 PM

$AMLX looks like a large order in the works! we could be seeing a filing coming on the back of this one and the ones from the last two sessions.

2 · Reply

Market Cap	1.57B
Revenue (ttm)	87.37M
Net Income (ttm)	-301.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-345.36%
Debt to Equity Ratio	0.00

Volume	1,405,300
Avg Vol	1,637,044
Day's Range	N/A - N/A
Shares Out	109.82M
Stochastic %K	13%
Beta	-0.31
Analysts	Strong Sell
Price Target	$20.22